AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+8.05%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$2.09B
AUM Growth
+$2.09B
(+4.3%)
Cap. Flow
+$237M
Cap. Flow
% of AUM
11.31%
Top 10 Holdings %
Top 10 Hldgs %
57.89%
Holding
113
New
16
Increased
20
Reduced
14
Closed
6
Top Buys
| 1 |
NVIDIA
NVDA
|
$75.4M |
| 2 |
Gossamer Bio
GOSS
|
$36M |
| 3 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$27.9M |
| 4 |
EPZM
Epizyme, Inc
EPZM
|
$21.7M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$20M |
Top Sells
| 1 |
ARRY
Array Biopharma Inc
ARRY
|
$12.2M |
| 2 |
BLUE
bluebird bio
BLUE
|
$11.8M |
| 3 |
CMTA
Clementia Pharmaceuticals Inc.
CMTA
|
$10M |
| 4 |
AnaptysBio
ANAB
|
$9.57M |
| 5 |
argenx
ARGX
|
$8.74M |
Sector Composition
| 1 | Healthcare | 74.84% |
| 2 | Consumer Discretionary | 19.28% |
| 3 | Technology | 3.6% |
| 4 | Real Estate | 0.42% |
| 5 | Communication Services | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Goldman Sachs
GS
$226B
| – | – | 0 | – | – |
|
102
Melco Resorts & Entertainment
MLCO
$3.88B
| – | – | 0 | – | – |
|
103
Morgan Stanley
MS
$240B
| – | – | 0 | – | – |
|
104
Micron Technology
MU
$133B
| – | – | 0 | – | – |
|
105
Neurocrine Biosciences
NBIX
$13.8B
| – | – | 0 | – | – |
|
106
Qualcomm
QCOM
$173B
| – | – | 0 | – | – |
|
107
Vale
VALE
$43.9B
| – | – | 0 | – | – |
|
108
Wells Fargo
WFC
$263B
| – | – | 0 | – | – |
|
109
Wynn Resorts
WYNN
$13.2B
| – | – | 0 | – | – |
|
|
CLVS
110
DELISTED
Clovis Oncology, Inc.
CLVS
| – | – | 0 | – | – |
|
|
MNTA
111
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| – | – | -200,000 | Closed | -$2.21M |
|
|
CMTA
112
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
| – | – | -850,000 | Closed | -$10M |
|
|
CELG
113
DELISTED
Celgene Corp
CELG
| – | – | 0 | – | – |
|